Capital flows, institutional positioning, and investment signals in healthcare innovation
OpenAI’s purchase of Orchestra Bio is small in dollars and large in meaning. The companies that build frontier AI models are now buyers, backers and competitors in the life sciences at the same time, and that changes the exit math, the risk map and the diligence checklist for healthcare venture capital. On October 20, 2026,…
Universities are accused of skimming two thirds of every research grant. The arithmetic says otherwise. The real waterfall starts after the money is spent, between 26,196 invention disclosures and 941 companies.
An eight-month-old startup with fewer than 10 people just commanded $400 million in stock. For healthcare investors, the signal is louder than the price tag. On April 3, 2026, Anthropic confirmed its acquisition of Coefficient Bio, a stealth biotech AI startup, in an all-stock deal valued at just over $400 million. The company had no…
ARK Invest sold $87M in Nvidia and Meta and redirected capital into Tempus AI, GeneDx, CRISPR Therapeutics, and other healthcare AI companies. This institutional rotation validates the exact thesis HVCF was built on.
March 2026 | Healthcare Venture Capital Fund Research Healthcare private equity reached a record $191 billion in disclosed deal value in 2025, surpassing the previous 2021 peak. Exit value rebounded to an estimated $156 billion, nearly triple the $54 billion posted in 2024. Yet a backlog of more than 16,000 portfolio companies globally, many held…
End of content
End of content